Cargando…

Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Mutations in Early Stage Patients

There is currently no blood-based marker in routine use for endometrial cancer patients. Such a marker could potentially be used for early detection, but it could also help to track tumor recurrence following hysterectomy. This is important, as extra-vaginal recurrence of endometrial endometrioid ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolivar, Ana M., Luthra, Rajyalakshmi, Mehrotra, Meenakshi, Chen, Wei, Barkoh, Bedia A., Peter Hu, Zhang, Wei, Broaddus, Russell R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395490/
https://www.ncbi.nlm.nih.gov/pubmed/30315273
http://dx.doi.org/10.1038/s41379-018-0158-8
_version_ 1783399100369076224
author Bolivar, Ana M.
Luthra, Rajyalakshmi
Mehrotra, Meenakshi
Chen, Wei
Barkoh, Bedia A.
Peter Hu,
Zhang, Wei
Broaddus, Russell R.
author_facet Bolivar, Ana M.
Luthra, Rajyalakshmi
Mehrotra, Meenakshi
Chen, Wei
Barkoh, Bedia A.
Peter Hu,
Zhang, Wei
Broaddus, Russell R.
author_sort Bolivar, Ana M.
collection PubMed
description There is currently no blood-based marker in routine use for endometrial cancer patients. Such a marker could potentially be used for early detection, but it could also help to track tumor recurrence following hysterectomy. This is important, as extra-vaginal recurrence of endometrial endometrioid adenocarcinoma is usually incurable. This proof-of-principle study was designed to determine if tumor-associated mutations could be detected in cell-free DNA from the peripheral blood of early and late stage endometrial endometrioid carcinoma patients. Approximately 90% of endometrioid carcinomas have at least one mutation in the genes CTNNB1, KRAS, PTEN, or PIK3CA. Using a custom panel targeting 30 hot spot amplicons in these 4 genes, next-generation sequencing was performed on cell-free DNA extracted from plasma obtained from a peripheral blood draw at the time of hysterectomy and the matching tumor DNA from 48 patients with endometrioid endometrial carcinomas. At least one mutation in the tumor was detected in 45/48 (94%) of patients. Fifteen of 45 patients (33%) had a mutation in the plasma that matched a mutation in the tumor. These same mutations were not detected in the matched negative control buffy coat. Presence of a plasma mutation was significantly associated with advanced stage at hysterectomy, deep myometrial invasion, lymphatic/vascular invasion and primary tumor size. Detecting a plasma-based mutation was independent of the amount of cell-free DNA isolated from the plasma. Overall, 18% of early stage patients had a mutation detected in the plasma. These results demonstrate that mutations in genes relevant to endometrial cancer can be identified in the peripheral blood of patients at the time of surgery. Future studies can help to determine the post-operative time course of mutation clearance from the peripheral blood and if mutation re-emergence is predictive of recurrence.
format Online
Article
Text
id pubmed-6395490
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-63954902019-04-12 Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Mutations in Early Stage Patients Bolivar, Ana M. Luthra, Rajyalakshmi Mehrotra, Meenakshi Chen, Wei Barkoh, Bedia A. Peter Hu, Zhang, Wei Broaddus, Russell R. Mod Pathol Article There is currently no blood-based marker in routine use for endometrial cancer patients. Such a marker could potentially be used for early detection, but it could also help to track tumor recurrence following hysterectomy. This is important, as extra-vaginal recurrence of endometrial endometrioid adenocarcinoma is usually incurable. This proof-of-principle study was designed to determine if tumor-associated mutations could be detected in cell-free DNA from the peripheral blood of early and late stage endometrial endometrioid carcinoma patients. Approximately 90% of endometrioid carcinomas have at least one mutation in the genes CTNNB1, KRAS, PTEN, or PIK3CA. Using a custom panel targeting 30 hot spot amplicons in these 4 genes, next-generation sequencing was performed on cell-free DNA extracted from plasma obtained from a peripheral blood draw at the time of hysterectomy and the matching tumor DNA from 48 patients with endometrioid endometrial carcinomas. At least one mutation in the tumor was detected in 45/48 (94%) of patients. Fifteen of 45 patients (33%) had a mutation in the plasma that matched a mutation in the tumor. These same mutations were not detected in the matched negative control buffy coat. Presence of a plasma mutation was significantly associated with advanced stage at hysterectomy, deep myometrial invasion, lymphatic/vascular invasion and primary tumor size. Detecting a plasma-based mutation was independent of the amount of cell-free DNA isolated from the plasma. Overall, 18% of early stage patients had a mutation detected in the plasma. These results demonstrate that mutations in genes relevant to endometrial cancer can be identified in the peripheral blood of patients at the time of surgery. Future studies can help to determine the post-operative time course of mutation clearance from the peripheral blood and if mutation re-emergence is predictive of recurrence. 2018-10-12 2019-03 /pmc/articles/PMC6395490/ /pubmed/30315273 http://dx.doi.org/10.1038/s41379-018-0158-8 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Bolivar, Ana M.
Luthra, Rajyalakshmi
Mehrotra, Meenakshi
Chen, Wei
Barkoh, Bedia A.
Peter Hu,
Zhang, Wei
Broaddus, Russell R.
Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Mutations in Early Stage Patients
title Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Mutations in Early Stage Patients
title_full Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Mutations in Early Stage Patients
title_fullStr Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Mutations in Early Stage Patients
title_full_unstemmed Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Mutations in Early Stage Patients
title_short Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Mutations in Early Stage Patients
title_sort targeted next-generation sequencing of endometrial cancer and matched circulating tumor dna: identification of plasma-based, tumor-associated mutations in early stage patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395490/
https://www.ncbi.nlm.nih.gov/pubmed/30315273
http://dx.doi.org/10.1038/s41379-018-0158-8
work_keys_str_mv AT bolivaranam targetednextgenerationsequencingofendometrialcancerandmatchedcirculatingtumordnaidentificationofplasmabasedtumorassociatedmutationsinearlystagepatients
AT luthrarajyalakshmi targetednextgenerationsequencingofendometrialcancerandmatchedcirculatingtumordnaidentificationofplasmabasedtumorassociatedmutationsinearlystagepatients
AT mehrotrameenakshi targetednextgenerationsequencingofendometrialcancerandmatchedcirculatingtumordnaidentificationofplasmabasedtumorassociatedmutationsinearlystagepatients
AT chenwei targetednextgenerationsequencingofendometrialcancerandmatchedcirculatingtumordnaidentificationofplasmabasedtumorassociatedmutationsinearlystagepatients
AT barkohbediaa targetednextgenerationsequencingofendometrialcancerandmatchedcirculatingtumordnaidentificationofplasmabasedtumorassociatedmutationsinearlystagepatients
AT peterhu targetednextgenerationsequencingofendometrialcancerandmatchedcirculatingtumordnaidentificationofplasmabasedtumorassociatedmutationsinearlystagepatients
AT zhangwei targetednextgenerationsequencingofendometrialcancerandmatchedcirculatingtumordnaidentificationofplasmabasedtumorassociatedmutationsinearlystagepatients
AT broaddusrussellr targetednextgenerationsequencingofendometrialcancerandmatchedcirculatingtumordnaidentificationofplasmabasedtumorassociatedmutationsinearlystagepatients